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The assembly and maintenance of the cardiac sarcomere, which contains the basic contractile com-
ponents of actin and myosin, are essential for cardiac function. While often described as a static struc-
ture, the sarcomere is actually dynamic and undergoes constant turnover, allowing it to adapt to
physiological changes while still maintaining function. A host of new factors have been identified that
play a role in the regulation of protein quality control in the sarcomere, including chaperones that
mediate the assembly of sarcomere components and ubiquitin ligases that control their specific degra-
dation. There is clear evidence of sarcomere disorganization in animal models lacking muscle-specific
chaperone proteins, illustrating the importance of these molecules in sarcomere structure and function.
Although ubiquitin ligases have been found within the sarcomere structure itself, the role of the ubiqui-
tin proteasome system in cardiac sarcomere regulation, and the factors that control its activity, are only
just now being elucidated. The number of ubiquitin ligases identified with specificity for sarcomere pro-
teins, each with distinct target substrates, is growing, allowing for tight regulation of this system. In this
review, we highlight the dynamic interplay between sarcomere-specific chaperones and ubiquitin-
dependent degradation of sarcomere proteins that is necessary in order to maintain structure and func-



















Cardiac contractility is regulated at the levels of calcium
homeostasis, cell signalling, and through the maintenance
of the sarcomere, the smallest contractile unit of cardiac
muscle. The assembly and turnover of the cardiac sarcomere
is essential to cardiac performance because it contains the
basic contractile components of actin and myosin necessary
for cardiac function. Given the importance of this basic
component of cardiac function, it is surprising that very
little is known about the actual mechanisms responsible
for its turnover. Most accounts of the sarcomere describe
it as a static structure used to generate force. However,
the sarcomere is actually a dynamic structure constantly
assembled and degraded by carefully regulated molecular
mechanisms that we are only just now beginning to identify
and understand.1 During the continuous contraction of the
cardiac sarcomere, new proteins are exchanged into the
structure via a carefully orchestrated process of synthesis
and degradation. This continual remodelling allows adap-
tation to stressors, including exercise, metabolic influences,
or disuse and must occur without affecting the integrity of
the contractile force necessary for the heart to continue
to function. Since this dynamic turnover of proteins
becomes more necessary in the face of cardiac pathologies
such as ischaemic heart disease and heart failure, it is essen-
tial to understand the mechanisms regulating the homeosta-
sis of the sarcomere.
As we understand it currently, the quality control system of
the sarcomere involves two main components: (1) chaper-
ones, which protect proteins from mis-folding and are necess-
ary for the assembly of specific major sarcomere components;
and (2) the ubiquitin proteasome system (UPS), which recog-
nizes specific proteins and targets them for degradation
(Figure 1). The specificity of the UPS machinery is afforded
by the ubiquitin ligases, which interact with E1 and E2
enzymes to place poly-ubiquitin chains on the substrates. It
is these poly-ubiquitin chains that the 26S proteasome recog-
nizes prior to substrate degradation (Figure 1). Several ubi-
quitin ligases have been identified that are integrated into
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the sarcomere of both skeletal and cardiac muscle, highlight-
ing the physical integration of the UPS and sarcomere. These
ligases include MuRF family proteins (MuRF1, MuRF2, and
MuRF3) and MAFbx/atrogin-1. Since the study of protein
quality control in the sarcomere is relatively new, much of
what we know on the subject has come from studies looking
at development of skeletal muscle. Insight into sarcomeric
dysregulation has been gleaned from examination of muscle
biopsy specimens taken from patients suffering from various
myopathies. In addition, the assembly and behaviour of indi-
vidual proteins making up the sarcomere have been studied
biochemically. In this review, we will take data obtained
from these various studies and use it to discuss the dynamic
process of cardiac sarcomere protein quality control, includ-
ing chaperones involved in the assembly of the sarcomere,
and the UPS and autophagy involved in the degradation of
the sarcomere.
2. Assembling the sarcomere
The basic components of the contractile apparatus of
muscle include myosin thick filaments (Figure 1, in red),
which act as molecular motors ratcheting down the actin
light chain (Figure 1, light green) during contraction.
There are many dozens of additional proteins that support
this basic interaction, such as the troponins and tropomyo-
sin that associate with actin and support myosin/actin
interactions, and proteins such as a-actinin that link adja-
cent sarcomeres at the z-disk (Figure 1, dark green).
Other essential structural proteins like titin (Figure 1,
blue) link the Z-disk to the M-line to stabilize myosin and
detect mechanical stress. In the established sarcomere,
integration and exchange of new proteins occurs continu-
ously as indicated by constituent t1/2 life of sarcomeric pro-
teins. Troponin subunits (T/I/C) have t1/2 lives of
approximately 3–5 days; actin and tropomyosin 7–10
days, while the t1/2 of myosin is approximately 5–8
days.2–4 The details of this replacement of contractile pro-
teins with newly synthesized proteins are not fully under-
stood; however, several recent studies have offered some
insight. For example, using epitope-tagged tropomyosin
(Tm) and troponin I (TnI) in adult cardiomyocytes, investi-
gators have been able to identify the incorporation of
newly synthesized myofilaments in differentiated
Figure 1 Sarcomere-specific chaperones and ubiquitin ligases are necessary for the assembly and degradation of sarcomere proteins and constitute the protein
quality control system in the heart. The protein quality control of the sarcomere involves the continuous assembly (left side) and degradation (right side) of
specific sarcomere proteins. In this example, the co-chaperones UNC-45 and Hsp90 are required for the assembly of myosin. This is balanced by the specific
ubiquitination and degradation of proteins by the ubiquitin proteasome system. This involves specific ubiquitin ligases (designated E3) that place poly-ubiquitin
tails on targets for degradation by the 26S proteasome. In this example, both MuRF1 and MuRF3 have shown to specifically ubiquitinate and degrade myosin in a
proteasome-dependent manner. In the heart, this dynamic process of protein quality control occurs amid continuous use in order to maintain the fundamental
construct necessary for contractility. Proteasome graphic courtesy of the U.S. Department of Energy Genome Programs (http://genomics.energy.gov).
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cardiomyocytes using confocal microscopy.5 This approach
revealed that TnI is initially detected along the entire
thin filament, whereas epitope-tagged Tm replaces
endogenous Tm only at the end of the thin filament.
These observations demonstrate that the movement of
myofilament proteins within the sarcomere is not a
random event, but instead is a highly ordered process, tai-
lored individually for each specific myofilament subtype.5
As will be discussed in the following sections, it is the job
of chaperones and the muscle-specific ubiquitin ligases to
ensure that the exchange of these sarcomere proteins
occurs seamlessly and without interruption to normal con-
tractile function.
2.1 Chaperones and actin assembly into
the sarcomere
Actin is a highly dynamic molecule subject to both polymer-
ization (into actin filaments) and aggregation. Correct
folding and prevention of aggregation of actin are essential
for the formation of thin filaments and their subsequent
interaction with myosin in the sarcomere. Two molecular
chaperones, GimC (Prefoldin) and TRiC (TCP-1 Ring
Complex), play a synergistic role in the folding and assem-
bling of actin. GimC attaches to actin as it is first translated
and assists in its initial folding, preventing the nascent actin
molecules from aggregating with one another.6 GimC then
acts as a co-chaperone and passes the actin filaments onto
the general chaperone TRiC, which mediates actin’s matu-
ration into filamentous actin.7–9 The subsequent process of
actin assembly into the thin filaments of the sarcomere is
not clear. However, it is known that TriC remains associated
with actin throughout this process—possibly to prevent
aggregation—and is able to modulate filament elongation
in vitro.9 Other chaperones, including aB-crystallin10–12
and Hsp2713 also reportedly associate with actin. Very
little is known about the functional significance of these
associations, however, in the case of Hsp27, the interaction
with actin does appear to be vital to cardiac and skeletal
muscle development in the assembly of actin filament and
myofibril assembly.13 These overlapping roles of chaperones
and targets suggest that a highly cooperative relationship
exists between various chaperones during the assembly of
the actin thin filaments of the sarcomere.
2.2 UNC-45, Hsp90, and Hsp70 participate in
myosin integration into the sarcomere
A detailed understanding of how myosin is incorporated into
the sarcomere spatially and temporally is not known.
However, it is known that—in contrast to the spontaneous
polymerization of actin in solution—myosin does not self-
assemble without additional factors.14 Much of what we
know about myosin assembly and its role in sarcomere organ-
ization comes from studies involving skeletal muscle develop-
ment in Caenorhabditis elegans. The assembly of myosin
requires multiple chaperones including UNC-45, Hsp90, and
Hsp70. UNC-45, the first member of the UNC family to be
identified, was named for the un-coordinated phenotype
that was seen in C. elegans when this protein was
mutated.15 The UNC-45 protein has two distinct binding
domains; on the N-terminal end UNC-45 has tetratricopep-
tide repeat (TPR) clamp domains while the C-terminal end
has a UCS (UNC-45/Cro1/She4) domain. Myosin binding to
UNC-45 through its UCS domain prevents myosin aggrega-
tion,16,17 whereas the N-terminal of UNC-45 contains a
region that binds to the more general chaperone proteins
Hsp90 and Hsp70,17,18 and is essential for the organization
of the thick filament experimentally.18–21 Mutations in con-
served regions of the unc-45 UCS domain result in reduced
numbers of myofilaments with severe disorganization.22
Vertebrates have UNC-45 homologues named UNC-45A and
UNC-45B, which may have conserved function. In mice and
humans, UNC-45A is found in many tissues, while the
UNC-45B homologue is found only in cardiac and skeletal
muscle.23 Anti-sense experiments in C2C12 skeletal myogenic
cells demonstrate the general cell isoform UNC-45A has a role
in proliferation and cell fusion, while UNC-45B has a role in
sarcomere organization.23 This is complementary to other
studies in zebrafish that have identified that UNC-45B and
Hsp90a co-localize with myosin during muscle development
and associate with the Z-line upon myofibril assembly.19,24
Consistent with the aforementioned studies in C. elegans,
vertebrate UNC-45B has a significant role in sarcomere
organization. Mammalian UNC-45B selectively binds unfolded
conformations of the myosin motor domain and promotes de
novo folding, indicating a fundamental role in myofibrillogen-
esis.25,26 While no definitive associations have been made
with UNC-45B and human disease, a statistical analyses has
identified UNC-45B (a.k.a. CMYA4) as a cardiomyopathy-
associated gene,27 although the role of UNC-45B in cardio-
myopathy and other cardiac diseases remains to be
elucidated.
Whereas UNC-45 regulates the process of folding and
assembly of myosin, the regulation of UNC-45 itself is care-
fully tuned by the UPS. The degradation of UNC-45 is mediated
by two ubiquitin ligases: (1) UFD-2 (Ubiquitin fusion
degradation-2); and (2) CHIP (C-terminal of Hsp70 interacting
protein).28 CHIP is both a molecular chaperone and ubiquitin
ligase, co-operating with Hsp70 and Hsp90 to target abnormal
proteins for degradation by ubiquitination.29,30 CHIP exerts
both chaperone and ligase activities on myosin and, as such,
CHIP is central to coordinating the folding and degradation
of this molecule. The stoichiometry of UFD-2 and CHIP to
UNC-45 appears to regulate the degradation of UNC-45. In
the presence of UFD-2 or CHIP individually, UNC-45 is ubiqui-
tinated with only 1–3 ubiquitin molecules, which is not suffi-
cient to target UNC-45 for degradation by the 26S
proteasome.28,31 In the presence of both UFD-2 and CHIP,
UNC-45 is markedly more ubiquitinated in vitro.28 Interest-
ingly, increasing UNC-45 in the presence of non-functional
UFD-2 and CHIP mutants results in defects in sarcomere
assembly.28,31 Although the exact process behind the sarco-
mere defect in this case is not known, it is possible that the
increase in UNC-45 may enhance the stabilization of myosin,
such that it is not available to form thick filaments necessary
for the assembly of the sarcomere.32 This stabilized yet unas-
sembled myosin may also be targeted for degradation,33 once
again leading to defects in sarcomere assembly.
2.3 Desmin assembly requires aB-crystallin
Desmin is an intermediate filament found at the Z-line of the
sarcomere that is necessary for sarcomere integrity. The
assembly of desmin requires the chaperone aB-crystallin, a
20 kDa peptide belonging to the family of small heat shock
proteins that is abundant in cardiomyocytes. aB-crystallin
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interacts with several cytoskeletal proteins, including
desmin,10,34 to prevent protein mis-folding. In addition,
similar to the chaperones associated with actin and
myosin, aB-crystallin can prevent desmin aggregation from
occurring.35,36 Mutations in either desmin or aB-crystallin
are the cause of numerous pathologies. Desmin-related myo-
pathies (DRM) are sporadic and familial myopathies caused
by mutations in either desmin or aB-crystallin. Patients
with these mutations have a striking loss of sarcomere organ-
ization, resulting in the loss of the myofibrillar integrity and
accumulation of desmin, aB-crystallin, and actin in the skel-
etal muscle and heart.37–43 Although the exact cause of this
family of myopathies has not been elucidated, evidence for
the mis-folding of desmin as the underlying cause of these
diseases has been reported both in vitro and in vivo.44–46
Mutations in either desmin or its chaperone aB-crystallin
also lead to accumulations of desmin-positive sarcomeric
inclusions that are associated with dilated cardiomyopa-
thy.42,43,47 Interestingly, these inclusions may reflect impair-
ments in both the chaperone and proteasome components
of protein quality control. Evidence suggests that improper
folding of desmin leads to toxic accumulations,48 that in
turn inhibit the proteasome, resulting in a failure to clear
the mis-folded proteins.26,49–51 It is interesting to note
that aB-crystallin interacts with FBX4, an F-box-containing
protein component of the SCF complex (SKP1/Cul1/F-box)
that has ubiquitin ligase activity.52 Mutant aB-crystallin
(i.e. R120G) has been reported to have enhanced interaction
with FBX4, stimulating the ubiquitination of yet to be
identified proteins.52 Together, these data suggest that
aB-crystallin may play a key role in both the assembly and
turnover of sarcomeres, thereby linking chaperone activity
with protein refolding and protein degradation through its
interactions with the UPS. aB-crystallin also interacts with
other central sarcomere proteins, such as titin53–56 and the
aforementioned actin. This may suggest a larger role for
aB-crystallin in the formation of the sarcomere.
3. The calpain and ubiquitin proteasome
systems mediate sarcomere degradation
The concept of UPS degradation of sarcomere proteins and
mediation of sarcomere turnover is relatively new. A
recent study in Drosophila using a conditional transgenic
system to disrupt proteasome function demonstrated wide-
spread muscle disorganization and induction of atrophy in
as little as 12 h after proteasome inhibition.57 By 24 h, all
movement was suspended and a loss of sarcomere organiz-
ation and parallel increases in autophagosomes and
expression of the chaperone GRP78 were identified.57
Therefore, global proteasome function appears necessary
for sarcomere stability.
3.1 Targeting proteins for proteasome degradation:
cardiac ubiquitin ligases
Several muscle-specific ubiquitin ligases have recently been
identified, including Muscle Ring Finger (MuRF) family pro-
teins, CHIP, murine double minute 2 (MDM2), and MAFbx/
atrogin-1.58,59 Their known and putative role in maintaining
the cardiac sarcomere is discussed below.
3.1.1 MuRF family proteins
MuRF1, found mainly in the M-line of the sarcomere where it
interacts with the giant protein titin, specifically recognizes
and degrades troponin I in a proteasome-dependent
manner.60 MuRF1 is reported to also interact with troponin
T, myosin light chain-2, myotilin, and telethonin.61 Interest-
ingly, the closely related MuRF2 protein also interacts with
these aforementioned proteins (at least experimentally),
suggesting that a redundant system may exist for turning
over these proteins.61 Supporting this theory is the finding
that, while mice deficient in either MuRF1 or MuRF2
develop normally, mice lacking both MuRF1 and MuRF2
develop cardiac hypertrophy during development.62 The
MuRF family of proteins has also been implicated in the
development of cardiac hypertrophy that occurs as a result
of mechanical stress. Mice lacking MuRF1 develop an exag-
gerated cardiac hypertrophy in response to transaortic con-
striction compared with wild-type mice, whereas, MuRF2
null mice develop cardiac hypertrophy to the same extent
as wild-type control mice.63 Despite the apparent lack of
involvement of MuRF2 in stress-induced cardiac hypertrophy
in vivo, Lange et al.64 demonstrated that MuRF2 can
mediate degradation of serum response factor and the inhi-
bition of cardiac hypertrophy signaling pathways64 in rat
neonatal cardiomyocytes following mechanical stress.
However, the in vivo significance of this finding is not yet
clear. Taken together, these findings suggest that while
MuRF1 and MuRF2 may have similar specificities in vitro,
their redundancy may be physiologically relevant during
cardiac development, and less important in the process of
cardiac hypertrophy induced in the adult heart.
MuRF1 and MuRF3 also interact cooperatively, in this case
with E2 enzymes (UbcH5a, b, and c), to degrade beta/slow
myosin heavy chain and MHCIIa in a proteasome-dependent
manner in the heart and skeletal muscle.65 Mice lacking
both MuRF1 and MuRF3 develop a hypertrophic cardiomyo-
pathy and skeletal muscle myopathy with MHC accumu-
lation, myofibre fragmentation, and impaired muscle
performance.65 Although the exact nature of how MuRF
family proteins target proteins for degradation is not
known, it has been suggested that MuRF may regulate the
turnover of specific proteins that have been worn or
damaged over time with use. While this hypothesis is cur-
rently untested, there is evidence that MuRF1 does play a
role in degrading damaged proteins. The enzyme creatine
kinase, which is essential for the delivery of ATP from the
mitochondria to all parts of cardiomyocytes, has recently
been suggested to be a MuRF1 substrate. Specifically,
MuRF1 is able to poly-ubiquitinate creatine kinase.66,67
Interesting, however, is the finding that MuRF1 preferen-
tially poly-ubiquitinates oxidized creatine kinase, a post-
translational modification that occurs after many types of
cellular stresses indicative of ‘cellular wear’.66,67 Because
creatine kinase isoforms are found at the M-line, where
MuRF1 is mainly localized in the sarcomere, this observation
supports the hypothesis that the ubiquitin ligase MuRF1 is
ensuring protein quality control by detecting damaged pro-
teins, perhaps through enhanced affinities, to allow the
essential continuous function of the heart.
3.1.2 C-terminus of Hsp70-interacting protein
The ubiquitin ligase CHIP has been recognized as an import-
ant factor involved in ischaemia reperfusion injury in the
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heart59 and in aging.68 Recent studies implicate CHIP in the
degradation of myosins during skeletal muscle loss in a C.
elegans model of Duchenne muscular dystrophy.69 CHIP
may therefore play an essential role in the turnover of
myosin as both a regulator of the UNC-45 co-chaperone (dis-
cussed previously), and as a ubiquitin ligase for myosin
directly.69
3.1.3 MAFbx/Atrogin-1 (muscle atrophy F-box)
Like MuRF1, MAFbx/Atrogin-1 was initially identified as a ubi-
quitin ligase essential to the process of skeletal muscle
atrophy (i.e. degradation of the sarcomere).58 Mice lacking
MAFbx/atrogin-1 do not undergo atrophy to the same extent
as wild-type mice, suggesting that MAFbx/atrogin-1 may
directly degrade specific sarcomere proteins.58 However,
unlike MuRF1, specific sarcomere protein substrates of
MAFbx/Atrogin-1 have not been identified. MAFbx/atrogin-1
has also been described as a regulator of several transcription
factors essential to regulation of cardiac hypertrophy.70,71
The specific role of MAFbx/atrogin-1 in the regulation of
yet-identified sarcomere substrates has yet to be determined
but remains a subject of intense scrutiny.
3.1.4 Murine double minute 2
MDM2 is a ubiquitin ligase that recognizes the N-terminal
activation domain of p53 to inhibit its transcriptional acti-
vation. In the heart, MDM2 is a critical regulator of apoptosis
through its ubiquitin-dependent degradation of ARC
(Apoptosis Repressor with Caspase recruitment domain).72
In the context of the sarcomere, MDM2 interacts with and
down-regulates the sarcomeric protein telethonin, in a
proteasome-dependent manner.73 The specific role MDM2
plays in the regulation of telethonin degradation in the
maintenance of the sarcomere has yet to be determined.
3.2 The calpain system is necessary for ubiquitin
ligases to reach sarcomere proteins
Calpains are a group of calcium-dependent, non-lysosomal
cysteine proteases expressed ubiquitously in all cells. As a
whole, calpains are not well understood, but it is known
that they are involved in a variety of cellular processes,
including cell-cycle control and cell fusion.74 Various
members of the calpain family have been localized to skel-
etal muscle where they are purported to be involved in
both muscle growth and atrophy.75,76 Calpain 1 has been
found in tight association with skeletal muscle myofibrils
where it binds tightly to the giant protein titin in a calcium-
dependent manner.77 Recently, it was discovered that
calpain-1 is required to mediate the dissociation of sarco-
mere proteins from the assembled myofibril before the
UPS system is able to degrade them (Figure 2). The UPS is
capable of degrading myofibrillar components, but only
when they are in their monomeric state; sarcomere proteins
found in multimeric complexes cannot be degraded by the
proteasome in vivo.78 When the calpain system is inhibited
in the heart, as in mice over-expressing calpastatin (an
endogenous calpain-specific inhibitor), morphological evi-
dence of widespread protein aggregation has been identified
along with increased autophagy (discussed in more detail in
the following section).79 This aggregation may represent
Figure 2 Cardiac calpain-1 is necessary for cardiac proteins to be ubiquitinated. In order for sarcomere proteins to be ubiquitinated by ubiquitin ligases,
calpain-1 activated release of the sarcomere appears necessary (left). Calpain-1 is also necessary for the regular turnover of aggregated proteins, which if
not cleared, can result in increased autophagy. Adapted from Galvez et al.79
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proteins not able to be degraded by the UPS in the absence
of calpain-1 intervention. This coordinated effort by calpain
and ubiquitin ligases is also illustrated in models of skeletal
muscle atrophy. Ubiquitin ligases, including MuRF1 and
MAFbx/atrogin-1, have proved to be essential in the
atrophic process. When calpain inhibitors are introduced
into the system, sarcomere degradation is inhibited,
thereby inhibiting muscular atrophy, without reducing
MuRF1 or MAFbx/atrogin-1 levels.80 This is consistent with
a pivotal role of the calpain system in allowing ubiquitin
ligases to mediate the degradation of the sarcomere.
Beyond its critical role in monitoring normal cardiac func-
tion, calpain-1 may also mediate pathological effects by
allowing enhanced ubiquitination of proteins to occur. In
cardiac-specific conditional calpain-1 transgenic mice,
widespread myocytolysis, cardiac hypertrophy, and inflam-
mation leading to heart failure was identified in mice
expressing increased calpain-1 activity levels.79 Since
several of the ubiquitin ligases that have been described in
the heart (i.e. MuRF1, MuRF3) recognize sarcomeric pro-
teins, understanding the role of the calpain system will be
critical to determine how they function in the heart.
4. Autophagy-dependent maintenance
of the sarcomere
In addition to the UPS-dependent sarcomere proteins (sum-
marized in Table 1), autophage-mediated degradation also
contributes to protein quality control of the sarcomere.
Autophagy removes invading pathogens, damaged organelles
(such as mitochondria), and mis-folded proteins through
lysosomal-mediated degradation of these materials
(Figure 3). Cardiac autophagy is initiated in response to
energy stress during periods of nutrient deprivation or high
metabolic demand, ischaemia/reperfusion injury, and
heart failure.81 Genetic models targeting the Atg family of
genes, more than 20 evolutionary conserved genes essential
to autophagy,82 demonstrate a fundamental role for autop-
hagy in cardiac function. Cardiac-specific deletion of a criti-
cal autophagy gene involved in vesicle elongation (Atg5) in
mice leads to global derangements in the sarcomere.83
Although cardiac organogenesis and development are not
perturbed in Atg5(2/2) mice, cardiac hypertrophy, left
ventricular dilation, and contractile dysfunction develop in
adulthood. Electron-micrographs of Atg5(2/2) hearts
reveal both a global derangement in sarcomere structure
and the misalignment and aggregation of mitochondria.83
Although cardiac abnormalities are not seen until adulthood
in these mice, induction of pressure overload in younger
animals does reveal a role for Atg in managing the response
to cardiac stress. Young Atg5(2/2) mice subjected to trans-
aortic constriction suffer a significant decrease in function
and increase in left ventricular dilation after only 1 week
of pressure overload, suggesting that autophagy is cardio-
protective during pathological stimulation. Furthermore,
using an in vitro model of ischaemia, over-expression of
another gene that functions in the elongation phase of
autophagy, Beclin 1 (also known as Atg 6), decreased,
whereas a dominant-negative form of Atg5 increased cellu-
lar injury,84 consistent with an adaptive/protective role
for autophagy.
Despite the somewhat overlapping roles of autophagy and
the UPS, these two pathways have only recently been
suggested to function cooperatively, particularly in the
heart. When autophagy is inactivated in Atg5 (2/2) mouse
hearts, there is an increase in poly-ubiquitinated proteins,83
which is surprising as the hearts of these mice also exhibit
increased proteasome activity that should ensure the clear-
ance of these tagged proteins. This suggests that the increase
in toxic protein aggregates caused by a lack of autophagy
overwhelms the UPS so that in spite of its compensatory
increase in activity, it is unable to clear the poly-ubiquitinated
proteins.85,86 This theory is supported by a more recent study
demonstrating that inhibition of proteasome activity in the
heart leads to the accumulation of poly-ubiquitinated pro-
teins and subsequent activation of autophagy.87 These find-
ings outline a cooperative role between the UPS and
autophagy in maintaining protein quality control in the
heart through a combination of targeting of monomeric pro-
teins via the UPS and degradation of protein aggregates and
damaged mitochondria via autophagy.
Accumulating data demonstrating a link between the UPS
and autophagy prompted studies looking at common regulat-
ory circuits, thus far limited to skeletal muscle. One emer-
ging pathway is the Akt-FOXO pathway, linking growth
factor signalling to the coordinated regulation of the protea-
somal and lysosomal systems (reviewed in refs. 88–90).
FOXO3 mediates both cardiac and skeletal muscle atrophy
through its direct activation of the muscle-specific ubiquitin
ligase Atrogin-1/MAFbx, promoting degradation of proteins
via the UPS (described earlier). Focusing on skeletal
muscle, studies from two independent groups demonstrated
an mTOR-independent circuit involving Akt-mediated regu-
lation of FOXO3.67,91 FOXO3 positively regulates the
expression of a cadre of autophagy-related genes, as seen
in mouse models of muscle atrophy such as denervation or
fasting, and is necessary and sufficient to activate autop-
hagy in skeletal muscle in vivo. The ability of Foxo3 to
up-regulate autophagy is also independent of the UPS
system. Thus Foxo3 has a unique role in its regulation of
both proteasomal and lysosomal systems.
5. Disruption of sarcomere protein quality
control disrupts sarcomere integrity
Although we have focused on the role of chaperones and
ligases in this review, malfunction of the assembly and
Table 1 Contributors to protein quality control of the sarcomere
Thin filament
Actin assembly GimC, TRiC, aB-crystallin, Hsp27
Troponin I degradation MuRF1
Thick filament
Myosin assembly UNC-45, Cro1, She4p, Hsp90, and
Hsp70
Myosin degradation CHIP, MuRF1, MuRF3







Autophagy Atg5, Beclin 1
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turnover of proteins may result from mutations in sarcomere
proteins themselves. Mutations in sarcomeric proteins,
including TnT, TnI, b-myosin heavy chain, and cardiac
myosin binding protein-C (recently reviewed by
Morimoto92), lead to a diverse array of cardiomyopathies.
Cardiac dysfunction in familial hypertrophic cardiomyopa-
thies results from defects in calcium signalling and delayed
relaxation.93–96 Recent studies have identified that
Figure 3 Regulation of protein quality control by autophagy. The best defined regulator of autophagy to date is the target of rapamycin (TOR) kinase, which
signals upstream of the Atg family of genes, which include more than 20 evolutionary conserved genes essential to autophagy.82 Target of rapamycin kinase is
regulated by growth factor signalling, such as Akt signalling, thereby completing a nutrient-sensitive autophagy regulatory circuit. Other ‘sensing’ molecules
contribute to autophagy activation, such as the energy sensor 50-AMP-activated protein kinase (AMPK) and the nutrient-sensitive eukaryotic initiation factor
2alpha (eIF2alpha). Autophagy describes a multi-step process (nucleation, elongation, and completion) of a double-membrane vesicle forming around cyto-
plasmic cargo developing into an autophagosome. Subsequent docking and fusion of the autophagosome with a lysosome forms an autolysosome and exposes
the cargo to lysosomal proteases leading to cargo degradation. Given the variety of stimuli that can activate autophagy, it is not surprising that multiple reg-
ulators of autophagy have been identified. For an exhaustive discussion of these and other regulatory proteins with a focus on disease pathogenesis, readers
are encouraged to read excellent recent reviews on this topic.107,108 Inset: Inhibiting autophagy, in this case by knocking out cardiac Atg5 in mice, leads to pro-
minent defects in the sarcomere structure, leading to sarcomere and mitochondrial disarray in the heart.83 Adapted from Levine and Kroemer.108
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truncated cMyBP-c mutations have an accelerated
proteasome-mediated degradation, leading to proteasome
impairment and toxic accumulation of proteins.96,97 So in
addition to the known biochemical defects resulting from
sarcomere mutations, specific genetic cardiomyopathies
may involve defects in cardiac protein quality control to
maintain the folding, assembly, and degradation necessary
for the proper maintenance of the heart.
6. Summary/Conclusions
The simple elegance of the static sarcomere structure has
given way to a theory of a complex, dynamic structure
that is in constant flux. The necessity of this turnover in
the heart is self-evident given its constant activity, periodic
stress, and vital necessity. In this review, we describe how
the two parallel processes of protein assembly and protein
degradation are necessary for the maintenance of the sarco-
mere. The process of sarcomere assembly is aided by cha-
perones such as GimC, TRiC and ab-crystallin that
associate with the various proteins that make up the myofi-
laments. The degradative process of sarcomere mainten-
ance is mediated in part by the UPS. Specifically, ubiquitin
ligases with sarcomere-specific interactions have been
identified, incl uding CHIP, MuRF1, MuRF2, MuRF3, and
MDM2 (see Table 1). In addition, recent studies have ident-
ified the need for calpain-1 activation in the heart for ubi-
quitin ligases, such as those just mentioned, to access the
sarcomere. Given the fact that each sarcomere may have
its own chaperone/ubiquitin ligase regulators, the complex-
ity of the turnover of the entire sarcomere is certainly just
beginning to be elucidated.
The maintenance of cardiac sarcomere function becomes
even more essential in the context of disease, where ade-
quate contractility is necessary for survival. Likewise, under-
standing these fundamental protein quality control
mechanisms in the heart will assist in the development of
specific therapies for conditions where maintenance and/or
recovery of sarcomere function is essential, such as in ischae-
mic heart disease and heart failure. Indeed, a major focus of
future research will be directed at identifying how the UPS
system balances the protein chaperone system in cardiac
disease, the importance of which is exemplified by the con-
tradictory effects of proteasome inhibitors on the heart.
While a number of studies have identified that proteasome
inhibition is beneficial in the face of ischaemia in animal
models,98–103 unexpected cardiotoxicity has been reported
in humans.104 A recent study identified that the proteasome
induced-cardiotoxicity in culture was due to a disequilibrium
between proteasome activity and ER chaperones.105,106 Over-
expressing ER chaperones reversed the proteasome inhibitor-
induced cardiomyocyte death.106 Both chaperone and protea-
some systems appear to be necessary to balance the dynamics
of protein synthesis and degradation in the heart. Thera-
peutic strategies that take advantage of the constant building
and remodelling of the heart may help in both the structural
and energetic changes that occur in disease.
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